RxDoctor Payments Data

Letitia Wood

Psychiatric/Mental Health · Wilmington, DENPI 1154906154

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 24.4% of the total. Reporting peaked in 2023 at $1,152 and has fallen 90.5% since, to $109 in 2025.

$2,695in general payments, 2019–2025

Across 132 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$659
  • Alkermes, Inc.$377
  • Otsuka America Pharmaceutical, Inc.$215
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$205
  • Axsome Therapeutics, Inc.$185
  • Johnson & Johnson$131
  • plus $923 from 15 others

What the payments were for

  • Food & beverage$2,695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,695 in reported general payments places this provider in the 80th percentile of 177 psychiatric/mental health providers in Delaware.

See all psychiatric/mental health providers in Delaware

Medicare billing

Part B allowed, 2024
$26,855
Medicare patients
25
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl16$36,874
Duloxetine Hcl34$2,254
Lamotrigine ErLamotrigine17$1,706
Venlafaxine Hcl ErVenlafaxine Hcl66$1,684
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine40$1,042
Zolpidem Tartrate ErZolpidem Tartrate17$879
Lamotrigine62$705
Olanzapine23$697
Bupropion XlBupropion Hcl29$569
Fluvoxamine Maleate15$547
Methylphenidate Hcl22$437
Trazodone Hcl37$425
Alprazolam66$424
Clonazepam26$284
Buspirone Hcl11$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$659$36,87416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 psychiatric/mental health providers in Delaware.

Other psychiatric/mental health in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →